Allarity Therapeutics, Inc. Operating Cash Flow
Allarity Therapeutics, Inc. (ALLR) reported Operating Cash Flow of -$7.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Allarity Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$2.56M.
- Allarity Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.49M.
- Allarity Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.24M.
- Allarity Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.41M.
- Allarity Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$14.82M.
- Allarity Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$17.35M.
- Allarity Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$12.74M.
- Allarity Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$16.82M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$7.06M 10-Q · filed 2026-08-14 | -$10.30M derived: sum of 3 quarters · filed 2026-08-14 | -$13.71M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | -$4.49M 10-Q · filed 2026-05-15 | -$7.74M derived: sum of 2 quarters · filed 2026-05-15 | -$11.15M derived: sum of 3 quarters · filed 2026-05-15 | -$16.63M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | -$3.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$6.65M derived: sum of 2 quarters · filed 2026-03-30 | -$12.13M derived: sum of 3 quarters · filed 2026-08-14 | -$14.82M 10-K · filed 2026-03-30 | |||
| 2025-09-30 | -$3.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$8.89M derived: sum of 2 quarters · filed 2026-08-14 | -$11.58M 10-Q · filed 2025-11-14 | -$14.78M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | -$5.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$8.17M 10-Q · filed 2026-08-14 | -$11.37M derived: sum of 3 quarters · filed 2026-08-14 | -$16.82M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | -$2.69M 10-Q · filed 2026-05-15 | -$5.89M derived: sum of 2 quarters · filed 2026-05-15 | -$11.34M derived: sum of 3 quarters · filed 2026-05-15 | -$18.64M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | -$3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$8.65M derived: sum of 2 quarters · filed 2026-03-30 | -$15.95M derived: sum of 3 quarters · filed 2026-03-30 | -$17.35M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | -$5.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$12.75M derived: sum of 2 quarters · filed 2025-11-14 | -$14.15M 10-Q · filed 2025-11-14 | -$15.82M derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | -$7.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | -$8.70M 10-Q · filed 2025-08-15 | -$10.38M derived: sum of 3 quarters · filed 2025-08-15 | -$15.75M derived: sum of 4 quarters · filed 2025-08-15 | |||
| 2024-03-31 | -$1.40M 10-Q · filed 2025-05-09 | -$1.49M 10-Q · filed 2024-05-14 | -$3.07M derived: sum of 2 quarters · filed 2025-05-09 | -$8.45M derived: sum of 3 quarters · filed 2025-05-09 | -$10.94M derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | -$1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$7.05M derived: sum of 2 quarters · filed 2025-03-31 | -$9.54M derived: sum of 3 quarters · filed 2025-03-31 | -$12.74M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$5.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$7.87M derived: sum of 2 quarters · filed 2024-11-14 | -$11.07M 10-Q · filed 2024-11-14 | -$13.52M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | -$2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$5.70M 10-Q · filed 2024-08-05 | -$8.14M derived: sum of 3 quarters · filed 2024-08-05 | -$12.55M derived: sum of 4 quarters · filed 2024-08-05 | |||
| 2023-03-31 | -$3.20M 10-Q · filed 2024-05-14 | -$5.65M derived: sum of 2 quarters · filed 2024-05-14 | -$10.05M derived: sum of 3 quarters · filed 2024-05-14 | -$14.26M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | -$2.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$6.85M derived: sum of 2 quarters · filed 2024-03-08 | -$11.06M derived: sum of 3 quarters · filed 2024-03-08 | -$16.82M 10-K · filed 2024-03-08 | |||
| 2022-09-30 | -$4.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$8.62M derived: sum of 2 quarters · filed 2023-11-14 | -$14.37M 10-Q · filed 2023-11-14 | -$18.69M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | -$4.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$9.96M 10-Q · filed 2023-08-14 | -$14.28M derived: sum of 3 quarters · filed 2023-08-14 | -$18.02M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | -$5.75M 10-Q · filed 2023-05-11 | -$10.07M derived: sum of 2 quarters · filed 2023-05-11 | -$13.81M derived: sum of 3 quarters · filed 2023-05-11 | -$18.07M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | -$4.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | -$8.05M derived: sum of 2 quarters · filed 2023-03-13 | -$12.32M derived: sum of 3 quarters · filed 2023-03-13 | -$14.89M 10-K · filed 2023-03-13 | -$15.05M 10-K · filed 2022-05-17 | ||
| 2021-09-30 | -$3.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$8.00M derived: sum of 2 quarters · filed 2022-11-14 | -$10.57M 10-Q · filed 2022-11-14 | -$9.74M 10-Q · filed 2021-11-23 | -$13.01M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | -$4.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-10-07 | -$6.83M 10-Q · filed 2022-10-07 | -$9.27M derived: sum of 3 quarters · filed 2022-10-07 | ||||
| 2021-03-31 | -$2.57M 10-Q · filed 2022-05-27 | -$5.01M derived: sum of 2 quarters · filed 2022-05-27 | |||||
| 2020-12-31 | -$2.44M derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-05-17 | -$7.25M 10-K · filed 2022-05-17 | |||||
| 2020-09-30 | -$4.81M 10-Q/A · filed 2022-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |